- Glecaprevir
-
- $1.00 / 1KG
-
2020-01-03
- CAS:1365970-03-1
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 200kg
Related articles - Glecaprevir-Pibrentasvir (Mavyret)
- MAVYRET is a prescription medicine used to treat adults and children 12 years of age and older or weighing at least 99 pounds ....
- Dec 21,2021
|
Product Name: | Glecaprevir | Synonyms: | Glecaprevir;(33R,35S,91R,92R,5S,E)-5-(tert-butyl)-N-((1R,2R)-2-(difluoromethyl)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)cyclopropyl)-14,14-difluoro-4,7-dioxo-2,8,10-trioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopentanacyclotetradecaphan-12-ene-35;Glecaprevir API;(1R,2R)-N-[[[(1R,2R)-2-[[4,4-Difluoro-4-(3-hydroxy-2-quinoxalinyl)-2-buten-1-yl]oxy]cyclopentyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-2-(difluoromethyl)-N-[(1-methylcyclopropyl)sulfonyl]cyclopropanecarboxamide cyclic (1→2)-ether;ABT-493(Glecaprevir);CS-2616;ABT-493;ABT 493;ABT493;GLECAPREVIR;Glecaprevir(ABT-493) | CAS: | 1365970-03-1 | MF: | C38H46F4N6O9S | MW: | 838.87 | EINECS: | | Product Categories: | | Mol File: | 1365970-03-1.mol | |
| Glecaprevir Chemical Properties |
Melting point | >186°C (dec.) | density | 1.46±0.1 g/cm3(Predicted) | storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere | solubility | DMSO (Slightly), Methanol (Slightly) | pka | 4.46±0.40(Predicted) | form | Solid | color | White to Off-White |
| Glecaprevir Usage And Synthesis |
Approval | On 19 December 2016, AbbVie submitted a new drug application to the U.S. Food and Drug Administration for the glecaprevir/pibrentasvir (trade name Mavyret) regimen for the treatment of all major genotypes of chronic hepatitis C. On 3 August 2017 the FDA approved the combination for hepatitis C treatment. In Europe, it was approved on 17 August 2017 for the same indication, under the trade name Maviret. | Uses | Glecaprevir is an antiviral drug used in the treatment of patients with hepatitis C virus (HCV) genotype 1-6, of special interest for the treatment of patients with chronic kidney disease also suffering from HCV. | Uses | Glecaprevir (INN) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals. It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir. Together they demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance in vitro. | Side effects | The most common adverse effects, observed in at least 10% of phase 3 trial participants, were headache and fatigue. |
| Glecaprevir Preparation Products And Raw materials |
|